BioLineRx presents data at SOBP demonstrating the potential benefit of BL-1020 in improving cognition

May 18, 2009
BioLineRx Ltd. (TASE: BLRX) announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented today at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver, Canada May 14-16, 2009.
The ability of BL1020 to improve episodic memory deficits suggests potential for the treatment of cognitive deficits in schizophrenia. EAGLE Phase 2b update- Independent Safety Monitoring Board reviews safety data of first 200 patients.
Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients